[p53 and Bax protein expression as predictor of chemotherapeutic effect in gastric carcinoma]

K Muguruma; B Nakata; K Hirakawa; Y Yamashita; N Onoda; T Inoue; T Matsuoka; Y Kato; M Sowa

[p53 and Bax protein expression as predictor of chemotherapeutic effect in gastric carcinoma]

Gan To Kagaku Ryoho. 1998 Apr:25 Suppl 3:400-3.

[Article in Japanese]

Authors

K Muguruma¹, B Nakata, K Hirakawa, Y Yamashita, N Onoda, T Inoue, T Matsuoka, Y Kato, M Sowa

Affiliation

¹ First Dept. of Surgery, Osaka City University Medical School.

PMID: 9589042

Abstract

This study was performed to estimate p53 and Bax overexpression as a predictor of the response to chemotherapy of patients with gastric cancer. The subjects were 20 patients with stage IV gastric cancer and 3 with locally recurrent lesions treated with 5-fluorouracil (5-FU) and low-dose cisplatin (CDDP) for 4 weeks. Of the total 23 patients, there were 10 responders: 2 showing complete response (CR) and 8, partial response (PR). Carcinoma biopsy specimens of all were obtained endoscopically with anti-p53 and anti-Bax antibodies. Of the 10 responders, 7 were in the negative p53 staining group, while of the 13 non-responders, 11 were in the positive p53 staining group (p = 0.013). But no correlation was demonstrated between the chemotherapeutic effect and Bax staining alone. Moreover, among the p-53-positive cases, the patients with Bax-negative tumors were all chemoresistant. Therefore, immunohistochemical identification of p-53 and Bax prior to chemotherapy may be a useful predictor for choice of non-responders to chemotherapy.

Publication types

English Abstract

MeSH terms

Adenocarcinoma / chemistry
Adenocarcinoma / drug therapy
Adenocarcinoma / pathology
Adenocarcinoma, Papillary / chemistry
Adenocarcinoma, Papillary / drug therapy
Adenocarcinoma, Papillary / pathology
Aged
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Apoptosis / drug effects*
Carcinoma, Signet Ring Cell / chemistry
Carcinoma, Signet Ring Cell / drug therapy
Carcinoma, Signet Ring Cell / pathology
Cisplatin / administration & dosage
Cisplatin / pharmacology
Drug Administration Schedule
Female
Fluorouracil / administration & dosage
Fluorouracil / pharmacology
Humans
Male
Middle Aged
Proto-Oncogene Proteins / metabolism*
Proto-Oncogene Proteins c-bcl-2*
Stomach Neoplasms / chemistry
Stomach Neoplasms / drug therapy*
Stomach Neoplasms / pathology
Tumor Suppressor Protein p53 / metabolism*
bcl-2-Associated X Protein

Substances

BAX protein, human
Proto-Oncogene Proteins
Proto-Oncogene Proteins c-bcl-2
Tumor Suppressor Protein p53
bcl-2-Associated X Protein
Cisplatin
Fluorouracil

Supplementary concepts

CF regimen